Medios AG Expands in Europe with Acquisition of Ceban Pharmaceuticals

Medios AG, a leader in Specialty Pharma Solutions in Germany, announced its acquisition of Ceban Pharmaceuticals B.V., a Dutch market leader in pharmaceutical compounding services. This move marks Medios's entry into the Netherlands, Belgium, and Spain, significantly internationalizing its business and laying the groundwork for a European Specialty Pharma platform.

Ceban, known for its rapid growth, is expected to have generated around €160 million in revenue and approximately €29 million in EBITDA (18% margin) by 2023. Medios will acquire 100% interest in Ceban for €235.3 million in cash and 1.7 million new Medios shares, valued at roughly €23.9 million. This transaction will employ both existing cash and a €200 million credit facility for financing, with the shares issued from authorized capital without subscription rights for shareholders.

The completion of this acquisition, subject to customary closing conditions, is anticipated in the second quarter of 2024. Medios expects this acquisition to boost its 2024 fiscal year revenue to between €1.9 and €2.1 billion, with an EBITDA ranging from €82 to €91 million, signifying a margin of about 4.3%.